Prognostic impact of post-chemoradiotherapy muscle quality in non-elderly adults with esophageal squamous cell carcinoma

Figure 1 Distribution of clinical characteristics stratified by survival status. KPS: Karnofsky Performance Status.

Figure 2 Post-treatment skeletal muscle density and associated factors in esophageal cancer patients. A-C: Boxplots of post-treatment skeletal muscle density (post-SMD) distribution across different clinical subgroups; D: Forest plot of multivariable logistic regression analysis for factors associated with post-SMD; E: The nonlinear association between age and post-SMD using restricted cubic spline analysis; F and G: The receiver operating characteristic curve and calibration curve of the age-based prediction model for post-SMD, respectively. OR: Odds ratio; 95%CI: 95% confidence interval; FPR: False positive rate; TPR: True positive rate; AUC: Area under the curve; Post-SMD: Post-treatment skeletal muscle density.

Figure 3 Survival analysis by post-treatment skeletal muscle density status stratified by age in esophageal cancer patients. A: The whole cohort; B: The ≥ 64 years cohort; C: The < 64 years cohort.

Figure 4 Prognostic model construction and validation based on post-treatment skeletal muscle density in patients aged < 64 years with esophageal squamous cell carcinoma. A: Kaplan-Meier survival curves stratified by risk score; B: Time-dependent receiver operating characteristic curves of the model; C and D: Bootstrap-based calibration curves for 12-month and 36-month overall survival prediction; E and F: Calibration curves for 12- and 36-month survival prediction. FPR: False positive rate; TPR: True positive rate; AUC: Area under the curve; SMD: Skeletal muscle density.